# Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-incorporating-clinical-outcome-assessments-into-endpoints-for-regulatory-decision-making/602cd947-34b1-41f2-adaf-e98010054159

> FDA guidance document: Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. Issue date: April 05, 2023. Get complete insights and analysis.

---

## Details

- Title: Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-04-05
- Comment Close Date: 2023-07-05
- Last Changed: 2023-04-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-0026">FDA-2023-D-0026</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments](https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome-assessments/2b824356-e323-42ee-9188-d57fbb4ec54d)
- [Early Alzheimer’s Disease: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/early-alzheimers-disease-developing-drugs-for-treatment/ef0ff9a7-7208-4951-acbb-acb9937f83e7)